GSE202434,GSE202438 12 V 14 TALAZOPARIB HUMAN UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE202434,GSE202438 12 V 14 TALAZOPARIB HUMAN UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE202434,GSE202438 12 V 14 TALAZOPARIB HUMAN UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE202434,GSE202438 12 V 14 TALAZOPARIB HUMAN UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE202434,GSE202438 12 V 14 TALAZOPARIB HUMAN UP.

Results found

Linked to

 

Label

Description

 

Gene

ZNF593 opposite strand

Gene

dynein axonemal heavy chain 2

Gene

mucolipin TRP cation channel 3

Gene

short chain dehydrogenase/reductase family 42E, member 1

Gene

PDZ domain containing 4

Gene

pregnancy specific beta-1-glycoprotein 8

Gene

ADP-ribosylhydrolase like 1

Gene

attractin like 1

Gene

islet cell autoantigen 1 like

Gene

leucine rich repeat protein 1

  • Gene

    ZNF593 opposite strand


  • Gene

    dynein axonemal heavy chain 2


  • Gene

    mucolipin TRP cation channel 3


  • Gene

    short chain dehydrogenase/reductase family 42E, member 1


  • Gene

    PDZ domain containing 4


  • Gene

    pregnancy specific beta-1-glycoprotein 8


  • Gene

    ADP-ribosylhydrolase like 1


  • Gene

    attractin like 1


  • Gene

    islet cell autoantigen 1 like


  • Gene

    leucine rich repeat protein 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.